Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world.

Infographic: Psoriasis (PsO)

Infographic: Psoriasis (PsO)

An overview of the PsO advanced therapy and systemic patient

Our PsO market snapshot offers an introduction to the real world patient data collected by our Therapy Watch PsO study. The snapshot features profile data for patients treated with advanced therapy agents and systemic agents.

read more »

  • Posted by Mariel Metcalfe
  • June 21, 2018
  • Articles

Scratching the surface: unmet needs in psoriasis

Scratching the surface: unmet needs in psoriasis

Director Mariel Metcalfe shares some key findings from a recent Living with psoriasis study conducted in Europe, which is now available to purchase

Psoriasis is a skin condition but its impact goes much further than skin-deep. The late US novelist John Updike, who had psoriasis from the age of six, talked about being ‘At War with my Skin’.
The martial metaphor is no exaggeration. Updike hesitated to use the term ‘disease’ for something “not contagious, painful, or debilitating”. Yet his psoriasis still had “the volatility of a disease, the sense of another presence co-occupying your body and singling you out from the happy herds of healthy, normal, mankind”.

read more »

  • Posted by Laurent Chanroux
  • March 30, 2017
  • Articles

What next for the treatment of Psoriasis in Europe?

What next for the treatment of Psoriasis in Europe?

Research Director Laurent Chanroux investigates the changing market dynamics in Psoriasis in Europe.

Over the last decade, systemic biologic therapies for Psoriasis (PsO) have become widespread and the development of biological therapies has revolutionized the treatment of the disease. A chronic autoimmune disease, psoriasis has an estimated prevalence of 2.5% in Europe, representing approximately 15 million people, with 20–25% of these suffering from severe disease.

read more »

  • Posted by Laurent Chanroux
  • March 17, 2016
  • Events, News

AAD Conference 2016

AAD Conference 2016

Therapy Watch recently presented “real-world” patient data on treatment duration and persistence among European PsO patients

We were delighted to present a poster at the 74th annual meeting of the American Academy of Dermatology, earlier this month. The poster, which is entitled: ‘A real world review of treatment duration and persistence among European psoriasis patients’ is authored by Research Director, Laurent Chanroux and Research Executive, Lauren Royel. 

read more »

  • Posted by Laurent Chanroux
  • February 5, 2015
  • Articles

2015: a good year for psoriasis drug development?

2015: a good year for psoriasis drug development?

Psoriasis (PsO) is a chronic immune-mediated disease estimated to affect more than 125 million people worldwide.

Psoriasis (PsO) is a chronic immune-mediated disease estimated to affect more than 125 million people worldwide. The condition is characterised by thick and extensive skin lesions (plaques), which can cause itching, scaling, and pain. These symptoms can often negatively impact patients’ quality of life, both psychosocially and physically, making daily functioning more difficult and increasing the risk for other chronic illnesses. Although a number of treatment options exist for PsO, there continue to be significant unmet needs in the market

read more »